This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

ICAD To Highlight Xoft System To Treat Skin, Breast And Gynecological Cancers At ASTRO

ASTRO Booth Number 2449-- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that its Xoft subsidiary will be showcasing its Xoft ® Axxent ® Electronic Brachytherapy System ® at the American Society for Radiation Oncology’s (ASTRO) 55 th Annual Meeting being held from September 22-25, 2013 in Atlanta at booth #2449. The Xoft System can be used to treat non-melanoma skin cancer (NMSC), early-stage breast cancer with Intraoperative Radiation Therapy (IORT) and Accelerated Partial Breast Irradiation (APBI), vaginal, endometrial and cervical cancer.

“This year’s activities at ASTRO demonstrate iCAD’s commitment to delivering targeted, innovative and cost-effective radiation therapy solutions to radiation oncologists to help them to more effectively treat a variety of cancers,” said Ken Ferry, President and CEO of iCAD. “It’s an exciting time for iCAD with new product introductions, significant progress in our post-market breast cancer study, and the presentation of longer term clinical data that supports the increased momentum of our NMSC application.”

The Company’s technology will be featured in the following educational sessions and at the Company’s booth:

Industry-Expert Theater

         
Topic: “Electronic Brachytherapy Utilizing the Xoft ® System for the Treatment of Non-Melanoma Skin Cancer”
 
Presentation: Monday, September 23 from 10:15 to 10:45 a.m.
 
Presenter: Ajay Bhatnagar, MD, MBA, Cancer Treatment Services Arizona, Affiliate of 21 st Century Oncology, Adjunct Assistant Professor of Radiation Oncology, University of Pittsburgh School of Medicine and DermEbx
 
Location: Rear of 100 Aisle, Exhibit Hall B1
 

New Data on the Use of the Xoft System for Non-Melanoma Skin Cancer (NMSC)

 
Topic: “Electronic Brachytherapy for the Treatment of Non-Melanoma Skin Cancer: Results at Three Years,” which presents new clinical data assessing adverse effects, cosmesis and recurrence rates related to high dose rate (HDR) electronic brachytherapy for the treatment of NMSC with the Xoft System.
 
Presentation: Tuesday, September 24 at 2:10 p.m.
 
Presenter: Dr. Bhatnagar
 
Location:

Scientific Session S in Room B405

 

Breast IORT Post-market Study Update

 
Topic: “A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) using the Xoft Axxent eBx System at the Time of Breast Conservation Surgery for Early-Stage Breast Cancer,” providing discussion of the ongoing study, which has 19 participating centers and more than 150 patients treated and which continues to enroll patients and enlist centers.
 
Presentation: Throughout Exhibit Hall hours
 
Location: iCAD Exhibit Booth 2449
 

About ASTRO

Radiation oncologists, medical physicists, dosimetrists, radiation therapists, radiation oncology nurses and nurse practitioners, biologists, physician assistants and practice administrators comprise ASTRO’s nearly 10,000 members, making it the largest radiation oncology organization of its kind. These medical professionals, found at hospitals, cancer treatment centers and academic research facilities around the globe, make up the radiation therapy treatment teams that are critical in the fight against cancer. Together, these teams, treat more than 1 million cancer patients each year.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,693.31 -82.81 -0.47%
S&P 500 2,055.96 -11.93 -0.58%
NASDAQ 4,862.1410 -38.7440 -0.79%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs